Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARQ 736 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ARQ 736 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ARQ 736 | DRUG | Subjects in this study will receive ARQ 736 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 900 mg/day (first cohort) and escalate until the recommended Phase 2 dose or maximum tolerated dose is determined. Cycles will be repeated in four-week (28-day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted. |
Inclusion Criteria: * Signed written informed consent granted prior to initiation of any study-specific procedures * Male or female subjects of ≥ 18 years of age * All subjects must be positive for a BRAF and/or NRAS mutation * Histologically or cytologically confirmed locally advanced, inoperable ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ARQ 736 is an investigational small molecule being studied for the treatment of advanced solid tumors that harbor BRAF and/or NRAS mutations. It is not approved for any indication and remains in clinical development. The only reported trial enrolled adults with these biomarker-selected tumors.
ARQ 736 is being developed by Merck & Company, Inc., which trades under the ticker MRK. The company sponsored the Phase 1 dose escalation study of ARQ 736 in patients with advanced solid tumors harboring BRAF and/or NRAS mutations.
ARQ 736 is in Phase 1 clinical development. It has completed one Phase 1 dose escalation trial in adult subjects with advanced solid tumors harboring BRAF and/or NRAS mutations. No later-phase trials have been reported, and the drug is not approved.
ARQ 736 has been evaluated in one completed Phase 1 trial, NCT01225536, titled Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations. The study enrolled 24 adults across sites in the United States and Italy.
No, ARQ 736 is not FDA approved. It is an investigational small molecule that has completed a single Phase 1 dose escalation study in advanced solid tumors with BRAF and/or NRAS mutations. It remains in clinical development and is not available as a marketed therapy.